Articles From: IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces the Filing of a Class Action on Behalf of Purchasers of Barrett Business Systems, Inc. - BBSI to IMRIS completes SYMBIS Surgical System human factors study


In December, Royce Focus Trust’s Board of Directors will meet to consider approving a new Investment Advisory Agreement for Royce Focus Trust (Nasdaq: FUND) with Sprott Asset Management, a Toronto-based alternative asset manager.
Sign-up for Important Information About Royce Focus Trust (Nasdaq: FUND) investment picks
Highly-acclaimed leader in ophthalmology adds clinical expertise to Board SAN DIEGO , Jan.
Sign-up for Imprimis Pharmaceuticals Appoints Dr. Richard L. Lindstrom to its Board of Directors investment picks
Patented formulation of alkalized lidocaine and heparin has been prescribed as a compounded drug for individual patients in different dosages in thousands of insurance reimbursed bladder instillation treatments for interstitial cystitis and painful bladder syndrome (IC/PBS) Formulation to form the cornerstone of the Imprimis Defeat IC™ physician and patient education campaign, which is expected to launch in early 2015 SAN DIEGO , Oct.
Sign-up for Imprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation investment picks
Dropless Cataract Therapy now available in California, Nevada, Oregon, and Hawaii SAN DIEGO , Dec.
Sign-up for Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Key Western States investment picks
Proprietary topical compounded formulations offer the promise of significantly reducing the number of patient eye drop administrations as well as the high cost of eye drops typically required for traditional treatment Results of an investigator-initiated evaluation of the company's Pred-Moxi and Tri-Moxi topical eye drops for patients following LASIK surgery expected to be announced by end of January 2015 SAN DIEGO , Jan.
Sign-up for Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops™ investment picks
Dropless cataract surgery created a "buzz" and was a "hot topic" at this year's AAO meeting SAN DIEGO , Oct.
Sign-up for Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting investment picks
2014/11/12
Patent-pending ophthalmic formulation revenues increased over 190% compared to the second quarter 2014 Company will host conference call today at 4:30 p.m. EST (1:30 p.m. PST) *Currently, all Imprimis compounded formulations may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.
Sign-up for Imprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments investment picks
Agreement to acquire Park Compounding marks an important milestone and a significant step forward to achieving nationwide distribution capability for Imprimis' patent-pending ophthalmic and urologic formulations SAN DIEGO , Dec.
Sign-up for Imprimis Pharmaceuticals Signs Agreement to Acquire PCAB-Accredited Pharmacy in California investment picks
Agreement represents the first distributor relationship outside the mainland United States for the company's ophthalmic formulations, which are now available by prescription in 36 states and US territories SAN DIEGO , Nov.
Sign-up for Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless™ Proprietary Formulations to Ophthalmologists in Puerto Rico investment picks
2015/1/13
Dropless Therapy™ injectable and planned LessDrops™ topical compounded formulations offer the same patent-pending technology and the promise of significantly reducing or completely eliminating the number of patient eye drop administrations.
Sign-up for Imprimis Pharmaceuticals to Highlight its Proprietary Ophthalmic Solutions at the Hawaiian Eye 2015 and the Cataract Surgery: Telling It Like It Is! Meetings investment picks
Imprivata ® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, today announced that Imprivata Cortext ® is the first secure communications platform for healthcare to integrate with XenMobile ®, a comprehensive enterprise mobility management (EMM) solution developed by Citrix.
Sign-up for Imprivata Announces First Secure Communications Solution for Healthcare to Integrate with Citrix XenMobile investment picks
Imprivata® (NYSE: IMPR) today announced that it expects its fourth quarter 2014 revenue to exceed the upper end of its previously announced guidance range of $26 to $27 million.
Sign-up for Imprivata Announces Record Revenues for 4Q2014 investment picks
Imprivata ® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, today introduced Imprivata OneSign ® 5.0 , the newest version of the company’s flagship authentication and access management solution.
Sign-up for Imprivata OneSign 5.0 Expands Capabilities of Healthcare Industry’s Leading Solution for Authentication Management and Virtual Desktop Access investment picks
Imprivata® (NYSE: IMPR) today announced that members of management will participate in the 33rd Annual J.P. Morgan Healthcare Conference.
Sign-up for Imprivata to Present at The 33rd Annual J.P. Morgan 2015 Healthcare Conference investment picks
Imprivata ® (NYSE: IMPR) today announced that members of management will participate in two upcoming investor conferences.
Sign-up for Imprivata to Present at Two Upcoming Investor Conferences investment picks
Imprivata® (NYSE: IMPR), a leading provider of authentication and access management solutions for the healthcare industry, today announced financial results for the third quarter of fiscal 2014.
Sign-up for Imprivata, Inc. Reports Third Quarter 2014 Financial Results investment picks
2015/01/16
Dominion is uniquely positioned to invest in high-ROIC energy infrastructure.
Sign-up for Improved Business Mix Sparks Moat Upgrade investment picks
Praxair, Inc. (NYSE:PX) announced today that the company will exhibit its most recent product introductions at the International Production and Processing Expo (IPPE) in Atlanta, Ga., January 27–29, 2015.
Sign-up for Improved Productivity for Processors: ColdFront™ Cryogenic Systems Featuring the ColdFront™ Cryo-Saver Tunnel Freezer at IPPE investment picks
2014/11/3
Unique needs of Baby Boomers, Generation X, and Millennials require personalized and streamlined communications LAKE SUCCESS, N.Y. , Nov.
Sign-up for Improving the Participant Experience is a Key Part in Addressing the Nation's Retirement Savings Shortfall, according to Broadridge Research investment picks
Company's report shows infrastructure improvements also drive economic growth in New Jersey NEWARK, N.J. , Nov.
Sign-up for Improving the Resiliency of the Electric Grid is Central to PSEG's Sustainability Strategy investment picks
2014/12/24
IMRIS Announces Closing of Private Placement Offering of Units Canada NewsWire MINNEAPOLIS , Dec.
Sign-up for IMRIS Announces Closing of Private Placement Offering of Units investment picks
2014/12/24
MINNEAPOLIS , Dec.
Sign-up for IMRIS Announces Closing of Private Placement Offering of Units investment picks
2014/12/22
IMRIS Announces Private Placement Offering of Units and Other Corporate Developments Canada NewsWire MINNEAPOLIS, MN , Dec.
Sign-up for IMRIS Announces Private Placement Offering of Units and Other Corporate Developments investment picks
2014/12/22
MINNEAPOLIS, MN , Dec.
Sign-up for IMRIS Announces Private Placement Offering of Units and Other Corporate Developments investment picks
18 US neurosurgeons from 9 leading institutions validate robot usability for final 510(k) submission deliverable MINNEAPOLIS, MN , Dec.
Sign-up for IMRIS completes SYMBIS Surgical System human factors study investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces the Filing of a Class Action on Behalf of Purchasers of Barrett Business Systems, Inc. - BBSI to IMRIS completes SYMBIS Surgical System human factors study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent